Wonderling D, Langham S, Buxton M, Normand C, McDermott C
Health Economics Research Group, Brunel University, Uxbridge, Middlesex.
BMJ. 1996 May 18;312(7041):1274-8. doi: 10.1136/bmj.312.7041.1274.
To provide a commentary on the economic evaluations of the Oxcheck and British family heart studies: direct comparison of their relative effectiveness and cost effectiveness; comparisons with other interventions; and consideration of problems encountered.
Modelling from cost and effectiveness data to estimate of cost per life year gained.
Middle aged men and women.
Screening for cardiovascular risk factors followed by appropriate lifestyle advice and drug intervention in general practice, and other primary coronary risk management strategies.
Life years gained; cost per life year gained.
Depending on the assumed duration of risk reduction, the programme cost per discounted life year gained ranged from 34,800 pounds for a 1 year duration to 1500 pounds for 20 years for the British family heart study and from 29,300 pounds to 900 pounds for Oxcheck. These figures exclude broader net clinical and cost effects and longer term clinical and cost effects other than coronary mortality.
Despite differences in underlying methods, the estimates in the two economic analyses of the studies can be directly compared. Neither study was large enough to provide precise estimates of the overall net cost. Modelling to cost per life year gained provides more readily interpretable measures. These estimates emphasise the importance of the relatively weak evidence on duration effect. Only if the effect lasts at least five years is the Oxcheck programme likely to be cost effective. The effect must last for about 10 years to justify the extra cost associated with the British family heart study.
对Oxcheck研究和英国家庭心脏研究的经济学评价进行评论:直接比较它们的相对有效性和成本效益;与其他干预措施进行比较;并考虑所遇到的问题。
根据成本和有效性数据进行建模,以估计每获得一个生命年的成本。
中年男性和女性。
在全科医疗中筛查心血管危险因素,随后给予适当的生活方式建议和药物干预,以及其他主要的冠状动脉风险管理策略。
获得的生命年;每获得一个生命年的成本。
根据假定的风险降低持续时间,英国家庭心脏研究中每获得一个贴现生命年的项目成本从为期1年的34,800英镑到为期20年的1500英镑不等,Oxcheck研究则从29,300英镑到900英镑不等。这些数字不包括更广泛的净临床和成本效应以及除冠状动脉死亡率之外的长期临床和成本效应。
尽管基础方法存在差异,但两项研究的经济学分析中的估计值可以直接比较。两项研究的规模都不足以对总体净成本提供精确估计。对每获得一个生命年的成本进行建模可提供更易于解释的指标。这些估计强调了关于持续时间效应的相对薄弱证据的重要性。只有当效应持续至少五年时,Oxcheck项目才可能具有成本效益。效应必须持续约十年才能证明与英国家庭心脏研究相关的额外成本是合理的。